文献速递脊柱关节炎

DESIR起始队列中轴型脊柱关节炎10年骶髂关节放射学进展

Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort.
PubMed 文献 · Ann Rheum Dis · 2024-06-12

基于DESIR队列(NCT01648907)评估近期起病轴型脊柱关节炎(<3年)患者10年随访中骶髂关节放射学进展及基线相关因素。完成者294例中mNY净进展者占5.8%;意向随访人群中mNY+概率每年增加0.87%(95%CI 0.56至1.19),10年累计8.7%,引入TNFi作为时变协变量后为每年0.45%(95%CI 0.09至0.81),10年累计4.5%;基线骶髂关节MRI骨髓水肿(BME)与mNY+相关(HLA-B27+者OR 6.2,95%CI 5.3至7.2;HLA-B27-者OR 3.1,95%CI 2.4至3.9)。

要点

  • 完成10年随访的294例中,从nr-axSpA进展为r-axSpA的净进展比例为5.8%。
  • 意向随访人群中mNY+概率每年增加0.87%(95%CI 0.56至1.19),10年累计8.7%。
  • 引入TNFi作为时变协变量后,mNY+概率每年增加0.45%(95%CI 0.09至0.81),10年累计4.5%。

核心结论

  • 近期起病轴型脊柱关节炎患者10年随访中从nr-axSpA转为r-axSpA的年度可能性低,考虑TNFi使用时更低。

研究设计与样本

  • 基于DESIR队列(NCT01648907)的分析,纳入近期起病(<3年)轴型脊柱关节炎患者。
  • 放射学状态依据改良纽约(mNY)标准,骨盆X线mNY信息在10年间分4个读片波次获取,图像盲法并由3名培训有素的读片者中心判读。
  • 完成者分析纳入基线及10年均具备骨盆X线的294例患者,意向随访分析纳入至少有一次可用mNY评分的659例参与者。

主要发现

  • 完成者中从nr-axSpA进展为r-axSpA的净进展比例为5.8%。
  • 意向随访人群中mNY+概率估计每年增加0.87%(95%CI 0.56至1.19),即10年后为8.7%。
  • 引入TNF抑制剂(TNFi)作为时变协变量后,mNY+概率为每年0.45%(95%CI 0.09至0.81),即10年后为4.5%。
  • 基线骶髂关节MRI骨髓水肿(BME)与随访中mNY+相关:HLA-B27+者OR 6.2(95%CI 5.3至7.2),HLA-B27-者OR 3.1(95%CI 2.4至3.9)。
  • 男性、症状持续时间>1.5年、轴型脊柱关节炎疾病活动度评分≥2.1及吸烟(仅HLA-B27阳性者)也与10年中mNY+相关。

关键数值与推荐

  • 放射学状态依据改良纽约(mNY)标准判定为放射学轴型脊柱关节炎(r-axSpA)或非放射学轴型脊柱关节炎(nr-axSpA)。
  • mNY净进展者百分比定义为进展者人数减退转者人数除以患者总数。
  • BME未发现是HLA-B27对10年mNY+效应的中介因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate sacroiliac radiographic progression over a 10-year follow-up and determine the baseline factors associated with such progression in patients with recent-onset axial spondyloarthritis (axSpA, <3 years). METHODS: This analysis was performed in the DESIR cohort (NCT01648907). The radiographic status of the patients (radiographic axSpA (r-axSpA) vs non-radiographic axSpA (nr-axSpA)) was based on the modified New York (mNY) criteria. Information on mNY criteria on the pelvic radiographs was obtained in four reading waves over a 10-year period. Images were blinded and centrally read by 3 trained readers. The % of mNY net progressors (ie, number of 'progressors' minus number of 'regressors' divided by the total number of patients) was assessed in completers (ie, pelvic radiographs at baseline and 10 years). The yearly likelihood of mNY+ was estimated using an integrated analysis (ie, including all patients with at least one available mNY score ('intention-to-follow' population) using a generalised estimating equations model and time-varying tumour necrosis factor (TNF) use as a confounder. Baseline predictors of mNY+ during 10 years were evaluated. RESULTS: Completers included 294 patients, while intention-to-follow included 659 participants. In the completers, the net % progression (from nr-axSpA to r-axSpA) was 5.8%. In the intention-to-follow population, the probability of being mNY+ was estimated to increase 0.87% (95% CI 0.56 to 1.19) per year (ie, 8.7% after 10 years) while when introducing TNF inhibitors (TNFi) as a time-varying covariate, the probability was 0.45% (95% CI 0.09 to 0.81) (ie, 4.5% after 10 years). Baseline bone marrow oedema (BME) on MRI of the sacroiliac joints (SIJ) was associated with being mNY+ over time OR 6.2 (95% CI 5.3 to 7.2) and OR 3.1 (95% CI 2.4 to 3.9) in HLA-B27+ and HLA-B27-, respectively). Male sex, symptom duration >1.5 years, Axial Spondyloarthritis Disease Activity Score ≥2.1 and smoking (only in HLA-B27 positives) were also associated with being mNY+ over 10 years. BME was not found to be a mediator of the HLA-B27 effect on mNY+ at 10 years. CONCLUSIONS: The yearly likelihood of switching from nr-axSpA to r-axSpA in patients after 10 years of follow-up was low, and even lower when considering TNFi use.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Molto A, López-Medina C, Sepriano A, et al. Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort. Ann Rheum Dis. 2024. PMID: 38423758. doi:10.1136/ard-2023-225184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。